Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
Animals
Carcinoma, Hepatocellular
/ genetics
Cell Line, Tumor
Cells, Cultured
Coculture Techniques
DEAD Box Protein 58
/ deficiency
Dendritic Cells
/ cytology
Gene Expression Regulation, Neoplastic
Humans
Liver Neoplasms
/ genetics
Male
Mice
Neoplasm Transplantation
Neoplastic Stem Cells
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Receptors, Immunologic
Signal Transduction
Smad2 Protein
/ metabolism
Transforming Growth Factor beta1
/ metabolism
Tumor Microenvironment
Up-Regulation
Hepatocellular carcinoma
Immune tolerance
Mixed lymphocyte reaction
Tumor microenvironment
Tumor-infiltrating dendritic cell
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
14 May 2019
14 May 2019
Historique:
received:
20
06
2018
accepted:
02
05
2019
entrez:
16
5
2019
pubmed:
16
5
2019
medline:
11
9
2019
Statut:
epublish
Résumé
Dendritic cells (DCs) alter their role from being immunostimulatory to immunosuppressive at advanced stages of tumor progression, but the influence of cancer stem cells (CSCs) and their secreted factors on generation and phenotypic change of DCs is unknown. Retinoic acid-inducible gene I (RIG-I) plays a role in regulation of other cellular processes including leukemic stemness besides its antiviral function. Short hairpin RNA-mediated gene silencing was employed to generate stable RIG-I-knocked-down human hepatocellular carcinoma (HCC) cell lines. Expression levels of genes and proteins in spheres of those HCC cells were determined by quantitative real-time PCR and Western bot, respectively. Levels of secreted cytokines were measured by ELISA. The surface molecule expression levels of DCs were analyzed using flow cytometry. The ability of DCs to induce proliferation of T cells was assessed by a mixed lymphocyte reaction (MLR) assay. RIG-I-knocked-down HCC cells showed upregulated expression of stem cell marker genes, enhanced secretion of factors suppressing in vitro generation of DCs into the conditioned medium (CM), and induction of a phenotype of tumor-infiltrating DCs (TIDCs) with low levels of DC markers in their tumors in nude mice. Those DCs and TIDCs showed reduced MLR, indicating RIG-I deficiency-induced immunotolerance. The RIG-I-deficient HCC cells secreted more TGF-β1 than did reference cells. The tumors formed after injection of RIG-I-deficient HCC cells had higher TGF-β1 contents than did tumors derived from control cells. DC generation and MLR suppressed by the CM of RIG-I-deficient HCC cells were restored by an anti-TGF-β1 antibody. TGF-β1-induced phosphorylation of Smad2 and Akt was enhanced in RIG-I-deficient HCC spheres, knockdown of AKT gene expression abolishing the augmentation of TGF-β1-induced Smad2 phosphorylation. Akt and p-Akt were co-immunoprecipitated with Smad2 in cytoplasmic proteins of RIG-I-deficient spheres but not in those of control spheres, the amounts of co-immunoprecipitated Akt and p-Akt being increased by TGF-β stimulation. Our results demonstrate that RIG-I deficiency in HCC cells induced their stemness, enhanced secretion and signaling of TGF-β1, tolerogenic TIDCs and less generation of DCs, and the results suggest involvement of TGF-β1 in those RIG-I deficiency-induced tolerogenic changes and involvement of CSCs in DC-mediated immunotolerance.
Sections du résumé
BACKGROUND
BACKGROUND
Dendritic cells (DCs) alter their role from being immunostimulatory to immunosuppressive at advanced stages of tumor progression, but the influence of cancer stem cells (CSCs) and their secreted factors on generation and phenotypic change of DCs is unknown. Retinoic acid-inducible gene I (RIG-I) plays a role in regulation of other cellular processes including leukemic stemness besides its antiviral function.
METHODS
METHODS
Short hairpin RNA-mediated gene silencing was employed to generate stable RIG-I-knocked-down human hepatocellular carcinoma (HCC) cell lines. Expression levels of genes and proteins in spheres of those HCC cells were determined by quantitative real-time PCR and Western bot, respectively. Levels of secreted cytokines were measured by ELISA. The surface molecule expression levels of DCs were analyzed using flow cytometry. The ability of DCs to induce proliferation of T cells was assessed by a mixed lymphocyte reaction (MLR) assay.
RESULTS
RESULTS
RIG-I-knocked-down HCC cells showed upregulated expression of stem cell marker genes, enhanced secretion of factors suppressing in vitro generation of DCs into the conditioned medium (CM), and induction of a phenotype of tumor-infiltrating DCs (TIDCs) with low levels of DC markers in their tumors in nude mice. Those DCs and TIDCs showed reduced MLR, indicating RIG-I deficiency-induced immunotolerance. The RIG-I-deficient HCC cells secreted more TGF-β1 than did reference cells. The tumors formed after injection of RIG-I-deficient HCC cells had higher TGF-β1 contents than did tumors derived from control cells. DC generation and MLR suppressed by the CM of RIG-I-deficient HCC cells were restored by an anti-TGF-β1 antibody. TGF-β1-induced phosphorylation of Smad2 and Akt was enhanced in RIG-I-deficient HCC spheres, knockdown of AKT gene expression abolishing the augmentation of TGF-β1-induced Smad2 phosphorylation. Akt and p-Akt were co-immunoprecipitated with Smad2 in cytoplasmic proteins of RIG-I-deficient spheres but not in those of control spheres, the amounts of co-immunoprecipitated Akt and p-Akt being increased by TGF-β stimulation.
CONCLUSIONS
CONCLUSIONS
Our results demonstrate that RIG-I deficiency in HCC cells induced their stemness, enhanced secretion and signaling of TGF-β1, tolerogenic TIDCs and less generation of DCs, and the results suggest involvement of TGF-β1 in those RIG-I deficiency-induced tolerogenic changes and involvement of CSCs in DC-mediated immunotolerance.
Identifiants
pubmed: 31088527
doi: 10.1186/s12885-019-5670-9
pii: 10.1186/s12885-019-5670-9
pmc: PMC6515680
doi:
Substances chimiques
Receptors, Immunologic
0
SMAD2 protein, human
0
Smad2 Protein
0
TGFB1 protein, human
0
Transforming Growth Factor beta1
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
RIGI protein, human
EC 3.6.1.-
DEAD Box Protein 58
EC 3.6.4.13
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
439Subventions
Organisme : Natural Science Foundation of Shandong Province
ID : ZR2014HM038
Références
Cytokine. 1999 Feb;11(2):151-6
pubmed: 10089137
J Exp Med. 1999 Jul 5;190(1):125-33
pubmed: 10429676
Korean J Intern Med. 2000 Dec;15(3):165-70
pubmed: 11242803
J Exp Med. 2002 Mar 4;195(5):547-58
pubmed: 11877478
Nat Rev Immunol. 2002 Jan;2(1):46-53
pubmed: 11905837
Anal Biochem. 1976 Jan;70(1):241-50
pubmed: 1259145
Nature. 2003 Oct 9;425(6958):577-84
pubmed: 14534577
J Biol Chem. 2004 Jan 23;279(4):2632-9
pubmed: 14610066
Nat Immunol. 2004 Jul;5(7):730-7
pubmed: 15208624
J Clin Oncol. 2006 Jan 10;24(2):306-14
pubmed: 16330671
Annu Rev Immunol. 2006;24:99-146
pubmed: 16551245
Cell. 2006 Jun 2;125(5):915-28
pubmed: 16751101
PLoS Biol. 2007 Mar;5(3):e67
pubmed: 17341133
Immunol Lett. 2007 Jun 15;110(2):110-20
pubmed: 17532057
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10553-8
pubmed: 18650396
Oncol Rep. 2008 Nov;20(5):1053-9
pubmed: 18949401
Cell Res. 2009 Jan;19(1):128-39
pubmed: 19114990
Cell Res. 2009 Jan;19(1):8-20
pubmed: 19114991
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73
pubmed: 19116269
J Immunol. 2009 May 15;182(10):6207-16
pubmed: 19414774
Nat Cell Biol. 2009 Jun;11(6):777-84
pubmed: 19448624
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1897-902
pubmed: 21224412
BMC Gastroenterol. 2011 Jun 14;11:71
pubmed: 21669008
J Clin Immunol. 2012 Jun;32(3):421-9
pubmed: 22289994
J Exp Med. 2012 Mar 12;209(3):495-506
pubmed: 22351930
PLoS One. 2013;8(2):e56367
pubmed: 23437118
Diabetes. 2013 Sep;62(9):3132-42
pubmed: 23715623
Int J Cancer. 2014 Jan 1;134(1):43-54
pubmed: 23784558
PLoS One. 2013 Aug 22;8(8):e72252
pubmed: 23991075
Cancer Cell. 2014 Jan 13;25(1):49-63
pubmed: 24360797
Mol Cell. 2014 Feb 6;53(3):407-19
pubmed: 24412064
Exp Hematol Oncol. 2014 Oct 17;3(1):25
pubmed: 25352995
J Immunol. 2015 Apr 1;194(7):2985-91
pubmed: 25795789
Int J Cancer. 2016 Jun 1;138(11):2570-8
pubmed: 26559373
BMC Cancer. 2015 Dec 24;15:1009
pubmed: 26704308
Oncotarget. 2016 May 17;7(20):29371-86
pubmed: 27105493
Oncotarget. 2016 Aug 30;7(35):57050-57065
pubmed: 27489353
Protein Cell. 2017 Mar;8(3):165-168
pubmed: 27815826
Int Immunopharmacol. 2017 Mar;44:183-190
pubmed: 28110064
J Biol Chem. 2017 Mar 10;292(10):4302-4312
pubmed: 28154170
Curr Opin Immunol. 2017 Apr;45:43-51
pubmed: 28192720
J Immunol. 2017 Jul 1;199(1):119-128
pubmed: 28550197
J Biol Chem. 1988 Jun 5;263(16):7741-6
pubmed: 3259578
Dev Genet. 1996;19(2):139-45
pubmed: 8900046